Clinton Group’s Novavax NVAX Stock Holding History

Clinton Group’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-5,237	Closed	-$220K	–	452
2018 Q1	$220K	Buy	+5,237	New	+$210K	0.02%	334

Other funds holding NVAX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Clinton Group's NVAX Position: Q2 2018 in Review

Clinton Group sold out of Novavax (NVAX) in Q2 2018, closing a stake of 5,237 shares — an estimated $220K sold.

Clinton Group first reported a position in NVAX in Q1 2018 and held it in 1 quarter. The position peaked at $220K in Q1 2018. 155 funds tracked by Wall St. Rank hold NVAX as of Q2 2018.

Clinton Group reported no remaining Novavax position as of Q2 2018 after selling out during the quarter.
Clinton Group sold 5,237 Novavax shares in Q2 2018, an estimated $220K.
Clinton Group first reported a position in Novavax in Q1 2018 and held it in 1 quarter.
Clinton Group's Novavax position peaked at $220K in Q1 2018.
155 funds tracked by Wall St. Rank held Novavax as of Q2 2018.

Based on Clinton Group's 13F filing for Q2 2018, filed 6 Jul 2018.